US panel to review Ovation's Sabril for epilepsy
This article was originally published in Scrip
The US FDA's peripheral and central nervous system drugs advisory panel will meet for two days next month to evaluate Ovation's epilepsy drug Sabril (vigabatrin). On August 6th the committee will discuss the NDA for adjunctive therapy in treating refractory partial seizures in adults. Vigabatrin's use for infantile spasms will be considered on August 7th. Both indications are undergoing a priority review; the user fee deadline was June 30th, but the FDA has informed the company that it expects to take an additional two months. Ovation said it anticipates receiving an action letter by the end of August and a final decision in the fourth quarter. The company acquired North American rights for Sabril, an irreversible GABA-transaminase inhibitor, from Aventis (nowSanofi-Aventis) in 2004. Vigabatrin is marketed for epilepsy in more than 50 countries but has been associated with visual field defects. The drug is also being tested in the US as a treatment for methamphetamine and cocaine dependence.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.